메뉴 건너뛰기




Volumn 10, Issue 2, 2003, Pages 46-54

Aripiprazole - Can a new pharmacological mode of action lead to a new quality in the treatment of schizophrenia?;Aripiprazol - Führt ein neuer wirkungsmechanismus zu einer neuen qualität in der schizophrenie-therapie?

Author keywords

Aripiprazole; Atypical neuroleptics; Effectiveness; Schizophrenia; Tolerability

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; PROLACTIN; QUETIAPINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; THIORIDAZINE; ZIPRASIDONE;

EID: 0037969912     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (4)

References (30)
  • 1
    • 0035041926 scopus 로고    scopus 로고
    • Antipsychotic-induced weight gain: A review of the literature
    • Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001;62(Suppl 7):22-31.
    • (2001) J Clin Psychiatry , vol.62 , Issue.SUPPL. 7 , pp. 22-31
    • Allison, D.B.1    Casey, D.E.2
  • 4
    • 0005221430 scopus 로고    scopus 로고
    • Aripiprazole vs. placebo in the treatment of stable, chronic schizophrenia
    • Jun 23-27, Montreal
    • Carson WH, Pigott TA, Saha AR, et al. Aripiprazole vs. placebo in the treatment of stable, chronic schizophrenia [Poster]. XXIII CINP Congress, 2002: Jun 23-27, Montreal.
    • (2002) XXIII CINP Congress
    • Carson, W.H.1    Pigott, T.A.2    Saha, A.R.3
  • 5
    • 0037393107 scopus 로고    scopus 로고
    • Switching patient to aripiprazole from other antipsychotic agents: A multicenter randomized study
    • Im Druck
    • Casey DE, Carson WH, Saha AR, Liebeskind A, et al., on behalf of the Aripiprazole Study Group. Switching patient to aripiprazole from other antipsychotic agents: A multicenter randomized study. Psychopharmacology 2003. Im Druck.
    • (2003) Psychopharmacology
    • Casey, D.E.1    Carson, W.H.2    Saha, A.R.3    Liebeskind, A.4
  • 6
    • 0005169169 scopus 로고    scopus 로고
    • Neurocognitive effects of aripiprazole vs. olanzapine in stable psychosis
    • Jun 23-27, Montreal
    • Comblatt B, Kern BS, Carson WH, et al. Neurocognitive effects of aripiprazole vs. olanzapine in stable psychosis [Poster]. XXIII CINP Congress, 2002: Jun 23-27, Montreal.
    • (2002) XXIII CINP Congress
    • Comblatt, B.1    Kern, B.S.2    Carson, W.H.3
  • 7
    • 0002050453 scopus 로고    scopus 로고
    • Aripiprazole, a novel antipsychotic: Overview of a phase II study result
    • Daniel DG, Saha AR, Ingenito G, et al. Aripiprazole, a novel antipsychotic: overview of a phase II study result [Abstract no. P.01.242]. Int J Neuropsychopharmacol 2000;3(Suppl 1): S157.
    • (2000) Int J Neuropsychopharmacol , vol.3 , Issue.SUPPL. 1
    • Daniel, D.G.1    Saha, A.R.2    Ingenito, G.3
  • 8
    • 0026611392 scopus 로고
    • The regulation of subcortical dopamine systems by the prefrontal cortex: Interactions of central dopamine systems and the pathogenesis of schizophrenia
    • Deutch AY. The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. J Neural Transm Suppl 1992;36:61-89.
    • (1992) J Neural Transm Suppl , vol.36 , pp. 61-89
    • Deutch, A.Y.1
  • 9
    • 0026751059 scopus 로고
    • Dopaminergic mechanisms in the pathogenesis of schizophrenia
    • Goldstein M, Deutch AY. Dopaminergic mechanisms in the pathogenesis of schizophrenia. FASEB J 1992;6:2413-21.
    • (1992) FASEB J , vol.6 , pp. 2413-2421
    • Goldstein, M.1    Deutch, A.Y.2
  • 10
  • 11
    • 0038142977 scopus 로고    scopus 로고
    • Sicherheit und verträglichkeit von aripiprazol
    • DGPPN 2002
    • Hippius H, Medori R, Kungel M, Saha AR, et al. Sicherheit und Verträglichkeit von Aripiprazol [Poster]. DGPPN 2002; Nervenarzt 2002;73(Suppl 1):190.
    • (2002) Nervenarzt , vol.73 , Issue.SUPPL. 1 , pp. 190
    • Hippius, H.1    Medori, R.2    Kungel, M.3    Saha, A.R.4
  • 12
    • 0031577960 scopus 로고    scopus 로고
    • 2 receptors following repeated treatment in the rat striatum
    • 2 receptors following repeated treatment in the rat striatum. Eur J Pharmacol 1997;321:105-11.
    • (1997) Eur J Pharmacol , vol.321 , pp. 105-111
    • Inoue, A.1    Miki, S.2    Seto, M.3
  • 13
    • 0037177358 scopus 로고    scopus 로고
    • The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1 α receptor
    • Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1 α receptor. Eur J Pharmacol 2002;441:137-40.
    • (2002) Eur J Pharmacol , vol.441 , pp. 137-140
    • Jordan, S.1    Koprivica, V.2    Chen, R.3
  • 14
    • 0036738786 scopus 로고    scopus 로고
    • Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder
    • Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:1-9.
    • (2002) J Clin Psychiatry , vol.63 , pp. 1-9
    • Kane, J.M.1    Carson, W.H.2    Saha, A.R.3
  • 15
    • 0012336529 scopus 로고    scopus 로고
    • Aripiprazole for long-term maintenance treatment of schizophrenia
    • Jun 23-27, Montreal
    • Kujawa M, Saha A, Ingenito G, Ali M, et al. Aripiprazole for long-term maintenance treatment of schizophrenia [Poster]. XXIII CINP Congress, 2002 Jun 23-27, Montreal.
    • (2002) XXIII CINP Congress
    • Kujawa, M.1    Saha, A.2    Ingenito, G.3    Ali, M.4
  • 16
    • 0012336529 scopus 로고    scopus 로고
    • Aripiprazol for long-term maintenance treatment of schizophrenia
    • Philadelphia; Abstract NR376
    • Kujawa M, Saha A, Ingenito GG, Ali M, et al. Aripiprazol for long-term maintenance treatment of schizophrenia. APA Annual Meeting 2002, Philadelphia; Abstract NR376.
    • (2002) APA Annual Meeting
    • Kujawa, M.1    Saha, A.2    Ingenito, G.G.3    Ali, M.4
  • 17
    • 0033151286 scopus 로고    scopus 로고
    • Interactions of the novel antipsychotic aripiprazole with dopamine and serotonin receptor sub-types
    • Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole with dopamine and serotonin receptor sub-types. Neuropsychopharmacology 1999;20:612-27.
    • (1999) Neuropsychopharmacology , vol.20 , pp. 612-627
    • Lawler, C.P.1    Prioleau, C.2    Lewis, M.M.3
  • 18
    • 0037410337 scopus 로고    scopus 로고
    • Aripiprazole in the treatment of schizophrenia: Safety and tolerability in short-term placebo-controlled trials
    • Im Druck
    • Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term placebo-controlled trials. Schizophr Res 2003. Im Druck.
    • (2003) Schizophr Res
    • Marder, S.R.1    McQuade, R.D.2    Stock, E.3
  • 20
    • 0242614131 scopus 로고    scopus 로고
    • Aripiprazole: A dopamine-serotonin system stabilizer
    • Jun 23-27, Montreal
    • McQuade RD, Burris KD, Jordan S, et al. Aripiprazole: a dopamine-serotonin system stabilizer [Poster]. XXIII CINP Congress 2002 Jun 23-27, Montreal.
    • (2002) XXIII CINP Congress
    • McQuade, R.D.1    Burris, K.D.2    Jordan, S.3
  • 21
    • 0036859532 scopus 로고    scopus 로고
    • 2-agonismus und dopaminerge stabilisierung, der neuartige wirkungsmechanismus des atypischen neuroleptikums aripiprazol
    • 2-Agonismus und dopaminerge Stabilisierung, der neuartige Wirkungsmechanismus des atypischen Neuroleptikums Aripiprazol. Psychopharmakotherapie 2002;9:120-7.
    • (2002) Psychopharmakotherapie , vol.9 , pp. 120-127
    • Müller, W.E.1
  • 23
    • 0001612909 scopus 로고    scopus 로고
    • Aripiprazole, a novel antipsychotic: Phase 2 clinical trial result
    • Petrie JL, Saha AR, McEvoy JP. Aripiprazole, a novel antipsychotic: phase 2 clinical trial result [Abstract no. P.2.114]. Eur Neuropsychopharmacol 1997;7(Suppl 2):S227.
    • (1997) Eur Neuropsychopharmacol , vol.7 , Issue.SUPPL. 2
    • Petrie, J.L.1    Saha, A.R.2    McEvoy, J.P.3
  • 24
    • 0038819745 scopus 로고    scopus 로고
    • Aripiprazole versus placebo in the treatment of stable, chronic schizophrenia
    • Philadelphia; Abstract NR314
    • Pigott TA, Saha AR, Ali MW, et al. Aripiprazole versus placebo in the treatment of stable, chronic schizophrenia. APA Annual Meeting 2002, Philadelphia; Abstract NR314.
    • (2002) APA Annual Meeting
    • Pigott, T.A.1    Saha, A.R.2    Ali, M.W.3
  • 25
    • 0038488945 scopus 로고    scopus 로고
    • Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder
    • Im Druck
    • Potkin SG, Saha AR, Kujawa MJ, Carson WH, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psych 2003. Im Druck.
    • (2003) Arch Gen Psych
    • Potkin, S.G.1    Saha, A.R.2    Kujawa, M.J.3    Carson, W.H.4
  • 27
    • 4244071100 scopus 로고    scopus 로고
    • Dopamine receptors and transporters in Parkinson's disease and schizophrenia
    • Seeman P, Niznik HB. Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J 1996;274:740-3.
    • (1996) FASEB J , vol.274 , pp. 740-743
    • Seeman, P.1    Niznik, H.B.2
  • 28
    • 0035204601 scopus 로고    scopus 로고
    • Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, Part 1. "Goldilocks" actions at dopamine receptors
    • Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, Part 1. "Goldilocks" actions at dopamine receptors. J Clin Psychiatry 2001;62:841-2.
    • (2001) J Clin Psychiatry , vol.62 , pp. 841-842
    • Stahl, S.M.1
  • 29
    • 0003096276 scopus 로고    scopus 로고
    • Aripiprazole and risperidone versus placebo in schizophrenia
    • Yeoung P, McQuade RD, Carson WH, Saha A, et al. Aripiprazole and risperidone versus placebo in schizophrenia. Eur Psychiatry 2002;17(Suppl 1):102-3.
    • (2002) Eur Psychiatry , vol.17 , Issue.SUPPL. 1 , pp. 102-103
    • Yeoung, P.1    McQuade, R.D.2    Carson, W.H.3    Saha, A.4
  • 30
    • 0035983682 scopus 로고    scopus 로고
    • 3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole: A study using positron emission tomography and (11C)raclopride
    • 3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole: a study using positron emission tomography and (11C)raclopride. Neuropsychopharmacology 2002;27:248-59.
    • (2002) Neuropsychopharmacology , vol.27 , pp. 248-259
    • Yokoi, F.1    Gründer, G.2    Biziere, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.